Transatlantic workshop: drug-related progressive multifocal leukoencephalopathy

  • Email
  • Help

Details

TitleTransatlantic workshop: drug-related progressive multifocal leukoencephalopathy
Date25/07/2011 - 26/07/2011
LocationEuropean Medicines Agency, London
SummaryA transatlantic two-day workshop co-chaired with the United States Food and Drug Administration (FDA) on drug-related progressive multifocal leukoencephalopathy (PML).

All documents

Name Language First published Last updated
Workshop proceedings - Transatlantic workshop on drug-related progressive multifocal leukoencephalopathy (PML) (English only) 08/09/2011  
Programme - Transatlantic workshop: Drug-related progressive multifocal leukoencephalopathy (PML) (English only) 05/04/2011 29/07/2011
Invitation for expressions of interest - Transatlantic workshop: drug-related progressive multifocal leukoencephalopathy (PML) (English only) 04/02/2011  
List of participants - Transatlantic workshop: Drug-related Progressive Multifocal Leukoencephalopathy (PML) (English only) 29/07/2011  
Presentation - Welcome, PML - Balancing risks and benefits - the patients' view, Christoph Thalheim (English only) 29/07/2011  
Presentation - The possible mechanisms of the disease, Eugene Major (English only) 29/07/2011  
Presentation - The outcomes of drug-induced PML, Joseph Berger (English only) 29/07/2011  
Presentation - Natalizumab (Tysabri) and PML - the current figures, Brigitte Keller-Stanislawski (English only) 29/07/2011  
Presentation - The relationship between PML-rituximab and other immunobiologicals: an overview, Renaud Du Pasquier (English only) 29/07/2011  
Presentation - The risk in transplanted patients, Marco Tuccori (English only) 29/07/2011  
Presentation - Activities in USA, the experience of FDA Neurology Division, Russel Katz (English only) 29/07/2011  
Presentation - PML: Risk communication in the EU, Rafe Suvarna (English only) 29/07/2011  
Presentation - Changes in the incidence of PML in Tysabri-treated patiens, Alice Hughes (English only) 29/07/2011  
Presentation - A common case definition for PML, Dirk Mentzer (English only) 29/07/2011  
Presentation - The Italian natalizumab registry, G. Tedeschi (English only) 29/07/2011  
Presentation - The TYSEDMUS Study, Christian Confavreux (English only) 29/07/2011  
Presentation - Industry Experience with PML, Carmen Bozic (English only) 29/07/2011  
Presentation - Development of models for testing possible treatments, Igor Koralnik (English only) 29/07/2011  
Presentation - Dicovery and development of PML treatments, Teresa Compton (English only) 29/07/2011  
Presentation - Evidence about plasma exchange in natalizumab related PML, Ralf Gold (English only) 29/07/2011  
Presentation - Immune Reconstitution Inflammatory Syndrome, Joseph Berger (English only) 29/07/2011  
Presentation - PML development, Heinz Wiendl (English only) 29/07/2011  
Presentation - Diagnosing PML, Joseph Berger (English only) 29/07/2011  
Presentation - Viral subtypes and the development of the disease: what is the evidence, Igor Koralnik (English only) 29/07/2011  
Presentation - The research in the field: Where to progress?, Eugene Major (English only) 29/07/2011  
Presentation - Regulators initiative, reserch agenda, Ana Hidalgo (English only) 29/07/2011  
Presentation - Research Agendas, Eugene Major (English only) 29/07/2011  
Presentation - The Interface of Academia and Clinical Practice, Joseph Berger (English only) 29/07/2011  
Presentation - PML consortium - industry, Susan Goelz (English only) 29/07/2011  
Presentation - Challenges and opportunities from public private partnerships, Richard Bergström (English only) 29/07/2011  
Presentation - The importance of clarity in relationships and transparency, Henry FItt (English only) 29/07/2011  
Presentation - Drug Safety Surveillance Initiatives, Gerald Dal Pan (English only) 29/07/2011  
Presentation - How to facilitate the communicationsdata exchange, Janice Soreth (English only) 29/07/2011  
Presentation - Public funding of research - EU perspective, Stefanie Prilla (English only) 29/07/2011  
Presentation - Public funding of research - US, Eugene Major (English only) 29/07/2011  
Presentation - The role of the pharmaceutical industry, Sophie Banzet (English only) 29/07/2011  
Presentation - Public Private Partnerships as funders, Hugh Laverty (English only) 29/07/2011  
Presentation - EU Regulators perspective, Peter Arlett (English only) 29/07/2011  
Presentation - US Regulators perspective, Russell Katz (English only) 29/07/2011  
Presentation - Industry PML consortium view, Sophie Banzet (English only) 29/07/2011  
Presentation - PML London Clinical Researchers perspective, Igor Koralnik (English only) 29/07/2011  
Presentation - Benefits of Public Health, Eugene Major (English only) 29/07/2011  
Presentation - Discussion 'progress for the benefit of public health', Ralf Gold (English only) 29/07/2011  
Presentation - What patients and caregivers want to happen now - priorities for action, Christoph Thalheim (English only) 29/07/2011  
Presentation - Benefits of Public Health, Eugene Major (English only) 29/07/2011  
Presentation - PML Final Conclusions, Peter Arlett (English only) 29/07/2011  

Media Videos


Related information